Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

The bacteria-based process, known as chemoenzymatic synthesis, produces a relatively high drug yield of about 40 percent, which is important for keeping manufacturing costs down. The resulting compound is not exactly identical to the existing synthetic heparin, called Arixtra, so the drug will still need to be tested in human clinical trials before it can reach the market. But the researchers showed that their heparin is nontoxic and works well as an anticoagulant in animals.

To make a commercial product, researchers will need to scale up the chemoenzymatic method from the milligram level of the university laboratory to the kilogram level of a pharmaceutical company. “That’s the big challenge,” says Jian Liu, a medicinal chemistry researcher at the University of North Carolina, Chapel Hill, and one of the lead authors of the study. “But theoretically this opens the door, and hopefully industry will realize the importance of this method.”

If all goes well, animal-derived heparin could be phased out within five to 10 years, says Jeremy Turnbull, a heparin expert at the University of Liverpool in the U.K., who wrote an editorial accompanying the study. “The new availability of chemoenzymatic options could be valuable for a number of disease treatments, including cancer,” he says. “It should be possible to scale the process up to kilogram level or higher, but no doubt it will take further effort.”

1 comment. Share your thoughts »

Tagged: Biomedicine, blood, heparin, synthesized chemicals

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me